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Defining the most penetrating correlates of protective memory T cells is key for designing
improved vaccines and T cell therapies. Here, we evaluate how interleukin (IL-2) production
by memory CD4 T cells, a widely held indicator of their protective potential, impacts immune
responses against murine influenza A virus (IAV). Unexpectedly, we show that IL-2-deficient
memory CD4 T cells are more effective on a per cell basis at combating IAV than wild-type
memory cells that produce IL-2. Improved outcomes orchestrated by IL-2-deficient cells
include reduced weight loss and improved respiratory function that correlate with reduced
levels of a broad array of inflammatory factors in the infected lung. Blocking CD70-CD27 sig-
nals to reduce CD4 T cell IL-2 production tempers the inflammation induced by wild-type
memory CD4 T cells and improves the outcome of IAV infection in vaccinated mice. Finally,
we show that IL-2 administration drives rapid and extremely potent lung inflammation involv-
ing NK cells, which can synergize with sublethal IAV infection to promote acute death.
These results suggest that IL-2 production is not necessarily an indicator of protective CD4
T cells, and that the lung environment is particularly sensitive to IL-2-induced inflammation
during viral infection.
Author summary
We show that memory CD4 T cell mediated protection against influenza A virus is inde-
pendent of the signature multifunctional cytokine IL-2 that is thought to define the most
protective memory cells. IL-2 deficient cells are more effective than wild-type memory
cells on a per cell basis at combating IAV and drive tempered early innate inflammatory
responses. Our studies define a clear and surprising role for IL-2 as a cytokine adjuvant
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within the lung that can synergize with virus driven acute inflammatory responses to
cause morbidity during sublethal respiratory viral infection.
Introduction
Interleukin-2 (IL-2) produced by CD4 T cells is thought to be critical for orchestrating optimal
immune responses by acting as an autocrine growth and survival factor [1] as well as a para-
crine cytokine to enhance the activity of other cell types, notably NK cells and CD8 T cells [2,
3]. IL-2 production by T cells is strictly regulated by antigen recognition and costimulatory sig-
nals, resulting in its transient secretion during cognate interactions with activated APC [4]. A
distinguishing feature of resting memory and memory-derived secondary CD4 T cell effectors
is their ability to produce higher levels of IL-2 more rapidly than naïve and primary CD4 T
effector cells [5, 6] and CD8 T cells [7, 8]. Consequently, memory CD4 T cells are the most
physiologically relevant source of IL-2 in vivo.
The capacity of Th1-polarized memory cells to co-produce high levels of IL-2 in combina-
tion with IFN-γ is widely held as a marker of superior protective capacity [9]. Indeed, memory
CD4 T cells marked by dual production of IFN-γ and IL-2 provide robust immunity against
influenza A virus (IAV) challenge in murine models [10–12]. Large numbers of memory cells
capable of producing IL-2 and responding rapidly against IAV have also been characterized in
human lungs [13, 14] and transcriptional signatures, phenotypes, and functional analysis sup-
port that lung-resident memory CD4 T cells are strong producers of IL-2 [12, 15]. Importantly,
the presence of increased numbers of IAV-specific memory CD4 T cells prior to seasonal
infection correlates with improved clinical outcome in human longitudinal studies [16]. Con-
versely, severe influenza disease has been associated with decreased levels of IL-2 in the lung
[17]. These findings support the concept that IL-2 production is essential for optimizing
immunity against IAV mediated by memory CD4 T cells. Here, we directly test this
hypothesis.
To overcome major technical and physiological barriers that prevent the straight forward
investigation of the impact of memory CD4 T cell-derived IL-2 in vivo, we generated memory
CD4 T cells specific for IAV in vitro from naïve TcR transgenic precursors in the presence of
exogenous IL-2 [5]. This model provides IL-2-dependent signals to IL-2-deficient (Il2-/-) CD4
T cells during priming that are essential to form most CD4 memory populations by program-
ing IL-7 receptor expression and rescuing effector cells from apoptosis [18, 19]. We used WT
and Il2-/- memory cells generated in this way in a well-established adoptive transfer model in
which naive host mice are challenged with IAV recognized by the donor cells. This reduction-
ist approach overcomes complications associated with long-term blockade of IL-2 or IL-2
receptors by antibody administration which has off target effects through the disruption of
FoxP3+ T regulatory (T reg) function that can independently impact the outcome of infections,
including secondary IAV challenge [20]. Additionally, while conditional knock-out models
that rely on the targeted expression of cre-recombinase to delete floxed genes are widely
employed, the efficiency of inducible knock systems dependent upon tamoxifen-induced cre-
recombinase expression can have varied efficiency within different tissues that can confound
observations [21].
Unexpectedly, we find that Il2-/- IAV-specific memory CD4 T cells provide superior protec-
tion against IAV compared to WT memory cells of the same specificity. Improved outcomes
associated with Il2-/- responses include wide-ranging reductions in the constituents of pulmo-
nary and systemic inflammation, accelerated viral clearance, improved pulmonary mechanics,
IL-2 drives potent inflammatory responses in the lung
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and reduced weight loss. We also show that blocking the CD70-CD27 costimulatory pathway
to dramatically reduce IL-2 production by memory CD4 T cells [19] tempers inflammation
and morbidity in an adoptive transfer model as well as in intact vaccinated wildtype mice.
Finally, we show that IL-2 administration to naive mice directly and rapidly upregulates a
broad array of cytokines and chemokines in the lung and synergistically enhances inflamma-
tion induced by IAV, indicating that the lung is particularly sensitive to IL-2 driven-inflamma-
tion. NK cells are major contributors to pulmonary IL-2-induced inflammation. Moreover,
NK cell depletion during IAV challenge of recipients of WT memory CD4 T cells phenocopies
the improved outcomes seen in Il2-/- memory CD4 T cell recipients.
Overall, our results indicate that memory CD4 T cell-derived IL-2 acts as a potent adjuvant
in the lung that enhances the production of a broad early inflammatory response during acute
viral infection. We find that IL-2 synergizes with pathogen-driven stimulation of innate immu-
nity to drive robust inflammatory responses that can worsen outcomes during primary IAV
infection as well as in models of memory CD4 T cell-mediated protection against lethal IAV
challenge. Our findings have important implications for therapies aimed at reducing the sever-
ity of IAV infection, for the correlates of protection used to design and evaluate T cell-based
vaccines, and for the consequences of respiratory infection during the clinical use of therapeu-
tics that result in increased levels of IL-2. This work may also help provide mechanistic insight
into the immunopathological impact of memory CD4 T cells induced by vaccination in mod-
els of chronic infection [22, 23].
Results
Increased levels of IL-2 are detected during heterosubtypic challenge of
IAV-primed mice
We previously found that IAV-specific lung-resident memory CD4 T cells generated from
naive TcR Tg donor cells displayed robust IL-2 production when assayed at day 30 post-infec-
tion and beyond [12]. We used shielding from labeling by i.v. administered anti-CD4 Ab to
discriminate lung-resident from circulating CD44hi CD4 T cells in intact IAV-primed mice
and found that the shielded cells displayed strong IL-2 production via intracellular cytokine
staining following stimulation with PMA and ionomycin (Fig 1A). This confirms that endoge-
nous, polyclonal lung-resident memory CD4 T cells display a strong capacity to produce IL-2.
We thus reasoned that IL-2 signals may have a greater impact on immune responses against
heterosubtypic IAV infection than during primary responses against IAV where IL-2-produc-
ing CD4 T cells only reach the lung in significant numbers at 6 or 7 days post-infection [24].
Indeed, we detected significant levels of IL-2 in the lungs of mice during the first week of het-
erosubtypic IAV infection while IL-2 was barely detectable during the same timeframe of a pri-
mary IAV response (Fig 1B).
In order to access the role of IL-2 production by memory CD4 T cells during their antigenic
recall, we used a previously validated model employing WT and Il2-/- TcR transgenic CD4 T
cells to generate memory populations from Th1-polarized effector populations in vitro [5].
Importantly, when transferred to naïve adoptive hosts that are then challenged with IAV, these
memory cell responses mirror key elements of the endogenous CD4 T cell recall response
against IAV [8, 10, 19]. Briefly, we provided exogenous IL-2 to cultures of naïve WT or Il2-/-
DO11.10 TcR transgenic cells [25] to program their capacity to form memory [19]. The result-
ing effectors cells were cultured in vitro in the absence of antigen and inflammatory signals for
3 days during which they transition to a resting state virtually indistinguishable from long-
term memory CD4 T cells generated in vivo [5, 19]. We have used such in vitro-generated
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memory cells in adoptive transfer studies to determine key mechanisms of CD4 T cell-medi-
ated protection against IAV [26, 27].
To clearly delineate protective functions of memory CD4 T cells versus those provided by
memory CD8 T cells, memory B cells, and other primed populations that would not be feasible
to block in intact IAV-primed mice [26], we transferred an equal number of WT or Il2-/-
DO11.10 memory cells to unprimed mice then infected with A/PR8-OVAII that contains the
OVA323-339 epitope recognized by the DO11.10 TcR. We gave 5x10
6 memory cells, which
results in ~5x105 cells able to respond factoring in a ‘10% take’ [28]. As previously discussed
[26], this number is in the range of the estimate of the total number of memory CD4 T cells
generated by IAV priming in BALB/c mice, as well as in studies analyzing DR-1 “humanized”
transgenic mice [29] in which the magnitude of the total HA-specific memory CD4+ T cell
response detected by ELISPOT assay alone is about 1x105 cells. Given that not all cells are
expected to make the cytokines assayed in the ELISPOT, and assuming that the response
against HA accounts for 20–50% of the total IAV specific cells [29, 30], a conservative estimate
of the total memory CD4 T cell pool is in the range of 2-5x105. The recipient mice were chal-
lenged with a lethal (2 LD50) dose of IAV against which 5x10
6 WT memory CD4 T cells pro-
tects [26] in order to test as stringently as possible the role of IL-2 production by the memory
CD4 T cells during a protective response.
Early memory CD4 T cell-enhanced inflammation is tempered in the
absence of IL-2
The earliest protective function of memory CD4 T cells upon cognate recognition of antigen
during IAV challenge is to ‘jump-start’ innate inflammatory responses in the lung. This innate
inflammatory response leads to marked control of viral titers within 3 days of infection (dpi),
is generated independently of Type I and II IFN, TNF, and pathogen associated molecular pat-
tern (PAMP) recognition [31], and is likely driven by resident memory T (TRM) cells. To ana-
lyze the role of IL-2 production by memory CD4 T cells in promoting this induction of innate
immunity, we assessed pulmonary inflammation in naïve recipients of WT or Il2-/- memory
CD4 T cells at 3 dpi with A/PR8-OVAII. As expected from previous studies [31], WT memory
CD4 T cells induced significantly higher levels of a broad spectrum of inflammatory cytokines
Fig 1. Increased levels of IL-2 are detected during heterosubtypic challenge of IAV-primed mice. IAV-primed
BALB/c were infected with 0.2 LD50 A/PR8 virus and IFN-γ and IL-2 production by CD44hi CD4 TRM analyzed at 65
dpi by ICCS following stimulation with PMA and ionomycin (a). Levels of IL-2 in lung homogenates on the indicated
days post 10 LD50 heterosubtypic A/PR8 virus challenge of unprimed and animals primed 35 days previously with
cold-adapted A/Alaska (b) (3–5 mice per group per day; 1 of 2 experiments). All error bars represent the standard
deviation.
https://doi.org/10.1371/journal.ppat.1007989.g001
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and chemokines by 3 dpi compared to control mice not receiving memory cells (represented
as dashed lines in graphs) (Fig 2). With the exception of TNF, IL-1α, and CCL5 that were
detected at levels comparable to those in hosts with WT memory CD4 T cells, recipients of
Il2-/- memory cells displayed markedly reduced levels of the factors analyzed (Fig 2A), the
majority of which were nevertheless significantly higher than in control mice. To evaluate how
long the inflammatory factors remained reduced in the Il2-/- versus WT memory CD4 T cell
recipients, we examined lung levels from 4–7 dpi. TNF, which is itself produced by WT and
Il2-/- memory CD4 T cells responding to IAV [19], remained similar. In contrast, IL-1α and
Fig 2. IL2-/- memory CD4 cells induce less inflammation than WT memory cells. Unprimed BALB/c recipients of
WT or Il2-/- memory DO11.10 CD4 T cells were challenged with a 2 LD50 dose of A/PR8-OVAII virus. On day 3,
inflammatory responses in lung homogenates were measured (a) (3 mice per group; 1 of 3 experiments). (b) The
amount of TNF, IL-1α, and IL-1β detected kinetically through 7 dpi (3 mice per group; 1 of 2 experiments). The
number of donor cells within the lung of recipients of WT or Il2-/- memory DO11.10 CD4 T cells (c), and the
frequency and MFI of donor IFN-γ production were also determined (d-f). In (a) the dashed line represents analyte
levels detected on 3dpi in the absence of memory CD4 T cell adoptive transfer and in (f) the dashed line represents
IFN-γ production from unstimulated controls. All error bars represent the standard deviation, and � P< 0.05, ��
P< 0.01, ��� P< 0.001, ���� P< 0.0001.
https://doi.org/10.1371/journal.ppat.1007989.g002
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IL-1β were reduced when assessed at day 4 and remained lower through 7 dpi in recipients of
Il2-/- memory CD4 T cells (Fig 2B). As no differences are seen in donor memory CD4 T cell
numbers or in IFN-γ production at d4 and d7 (Fig 2C–2F), these results suggest that IL-2 pro-
duction from memory CD4 T cells promotes potent, acute, and broad production of inflam-
matory factors in the lung of naïve recipient mice. The kinetic timeframe of the memory CD4
T cell-driven enhanced lungs of recipient mice inflammatory response observed here mirrors
previous findings and is in line with the response seen in IAV-primed mice post-heterosubty-
pic challenge [31].
IL-2 from memory CD4 T cells is not required for protection against IAV
The changes seen above could impact the ability of WT versus Il2-/- memory CD4 T cells to
protect against infection. To evaluate this, we assessed a number of parameters associated with
recovery from IAV challenge including morbidity, mortality, and viral clearance. All naïve
recipients of memory CD4 T cells survived, while control mice not receiving memory cells suc-
cumbed by 10 dpi (Fig 3A). Strikingly though, recipients of Il2-/- memory CD4 T cells began
to recover weight 2–3 days earlier than WT recipients (Fig 3B). The improved kinetics of
weight recovery in Il2-/- memory CD4 T cell recipients correlated with modest but significantly
accelerated viral clearance at 8 and 10 dpi (Fig 3C). When the number of cells transferred was
titrated, the enhanced protective capacity of Il2-/- memory CD4 T cells was even more evident
(Fig 3D), supporting the concept that reduced inflammatory responses driven by the memory
CD4 T cells in the absence of IL-2 signaling correlate with improved outcomes.
As in previous studies [19], we found no differences between the frequency and proliferation
of WT and Il2-/- memory CD4 T cells in the spleen, draining lymph nodes, and lungs on 4 and 7
dpi (S1 Fig), indicating that the enhanced protective capacity of Il2-/- memory CD4 T cells and
differences in the inflammatory response observed are not due to differences in the kinetics or
peak magnitude of WT versus Il2-/- memory CD4 T cell responses. Similar patterns of improved
recovery in recipients of Il2-/- memory cells were seen in nude hosts lacking T cells, JHD hosts
lacking B cells, and SCID hosts deficient in both T and B cells (S2 Fig). These observations argue
against the possibility that altered helper functions impacting anti-viral B cells or CD8 T cell
responses, or altered activity of IL-2 dependent host regulatory T cells impact the differences seen.
We and others previously found significant differences in the pulmonary function of unpro-
tected versus protected animals during the first week of IAV challenge [32–34]. We thus ana-
lyzed respiratory mechanics in naïve recipients of WT or Il2-/- memory CD4 T cell and found
that recipients of Il2-/- cells demonstrated improved respiratory rates and pulmonary minute
volumes from 4 to 5 dpi. On 6 dpi, both groups of memory CD4 T cells recipients began to
show signs of recovery in respiratory rates and only minute volumes remained significantly dif-
ferent (Fig 3E). Furthermore, lower levels of serum albumin, a measure of vascular leak, were
detected in the bronchoalveolar lavage of Il2-/- versus WT memory CD4 T cell recipients on 5
and 6 dpi (Fig 3F), indicating reduced pulmonary edema. Interestingly, histopathologic analysis
of the lung did not reveal marked differences between recipients of WT or Il2-/- cells at 7 dpi
(Fig 3G and 3H). Together, these results indicate that early IL-2 production by memory CD4 T
cells responding to IAV amplifies inflammatory responses that impair pulmonary function and
promote pulmonary edema without causing measurable increases in immunopathology.
Blocking CD70-mediated signaling tempers memory CD4 T cell-dependent
inflammation
Given that memory CD4 T cell derived-IL-2 appears to amplify IAV-associated inflammatory
responses, modulating IL-2 production may serve as a therapeutic strategy to decrease
IL-2 drives potent inflammatory responses in the lung
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morbidity. Treating mice with a blocking antibody against CD70 significantly reduces IL-2
and IFN-γ production from memory CD4 T cells responding in the lung at 7 dpi with IAV
(Fig 4A and 4B) but does not impact their response kinetics or ability to control virus [19].
Similar control of IL-2 production from CD4 and CD8 T cells by CD70-dependent signals has
been found in other infection models [35, 36]. We thus asked if blocking CD70 as a means to
reduce IL-2 production could improve the outcome of WT memory CD4 T cell-mediated pro-
tection. Much like the recipients of Il2-/- memory CD4 T cells in Fig 2, recipients of WT
Fig 3. IL-2 production is not needed for IAV-specific memory CD4 T cell-mediated protection. Unprimed BALB/c
hosts received WT or Il2-/- memory DO11.10 CD4 T cells and were challenged with a 2 LD50 dose of A/PR8-OVAII
virus. Survival (a), morbidity (b), and viral titer (c) were assessed (3–5 mice per group per day; 1 of 3 experiments). In
separate experiments, the number of adoptively transferred memory CD4 T cells was varied as indicated and (d)
survival during lethal infection monitored (5 mice per group, 1 of 3 experiments). On the indicated days, respiratory
rate, minute volume (e), BAL albumin levels (f), as well as histopathology on 7 dpi (g and h) were assessed,
representative images of lungs at 40X are shown (3–15 mice per group per day; 1 of 2 experiments). All error bars
represent the standard deviation and � P< 0.05, �� P< 0.01, ��� P< 0.001).
https://doi.org/10.1371/journal.ppat.1007989.g003
IL-2 drives potent inflammatory responses in the lung
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memory CD4 T cells treated with anti-CD70 antibody showed reduced levels of IL-1α, IL-1β,
IFN-γ, IL-6, IL-17, CCL2 (MCP-1), CXCL1 (KC), and IL-12 (Fig 4C), many of which are asso-
ciated with exacerbated IAV infection [37–40]. In contrast to these observations, we previously
Fig 4. Blocking CD70-mediated signaling tempers early memory CD4 T cell-driven inflammation during IAV.
Unprimed BALB/c recipients of memory WT DO11.10 CD4 T cells were infected with a 2 LD50 dose of A/PR8-OVAII
virus and treated with isotype or anti-CD70 blocking antibody (Ab). On 7 dpi, IFN-γ and IL-2 production by donor
cells in the lungs was determined by ICCS following peptide stimulation (a). Representative cytokine production is
shown in (b). On day 3, inflammatory responses (c) and levels of IL-2 (d) in lung homogenates were measured and are
presented (3 mice per group; 1 of 3 experiments). In separate experiments, morbidity (e) was assessed in recipients of
WT memory CD4 T cells as well as (f) following 10 LD50 heterosubtypic virus recall challenge of CD8 depleted, cold-
adapted A/Alaska-primed animals treated with anti-CD70. In separate groups of animals treated as in (f), anti-IL-2
neutralizing Ab or IL-2C containing 2 μg of IL-2 was administered i.p. for 4 days and recovery from morbidity
monitored (g) (3–4 mice per group; 1 of 2 experiments). All error bars represent the standard deviation, and �
P< 0.05, �� P< 0.01, ��� P< 0.001, and ���� P< 0.0001.
https://doi.org/10.1371/journal.ppat.1007989.g004
IL-2 drives potent inflammatory responses in the lung
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found memory CD4 T cell-induced levels of IL-1, IL-6, CCL2, CXCL1, and IL-12 to be similar
in WT and IFN-γ-receptor knockout mice following IAV challenge [31], arguing against
changes in IFN-γ production by memory CD4 T cells following anti-CD70 antibody treatment
contributing to the patterns seen in Fig 4C. Instead, the significantly lower amount of IL-2 in
lung homogenates with CD70 blockade (Fig 4D), supports the position that a reduction in the
amount of IL-2 available for paracrine signaling plays a major role in the tempered inflamma-
tory responses observed. The reduced inflammatory response and corresponding small but
significant reduction in weight loss and faster recovery (Fig 4E) seen with CD70 blockade
largely phenocopies observations with Il2-/- memory CD4 T cell transfer in Figs 2 and 3.
To test whether blocking CD70 to reduce memory CD4 T cell-driven inflammation could
improve outcomes in a more translational setting, naïve WT mice were primed with a cold-
adapted vaccine strain of IAV (A/Alaska; H2N2) and were challenged after 35 days with A/PR8
(H1N1). Groups of primed mice were treated with CD70 blocking antibody or an isotype con-
trol only during heterosubtypic A/PR8 infection. Given that memory CD8 T cell responses are
largely independent of CD27:CD70 signaling [41] and since they can provide strong protection
independently of the CD4 T cell recall response [42], to specifically address the isolated impact
of CD4 T cell mediated protection IAV-primed mice were also depleted of CD8 T cells prior to
heterosubtypic challenge. All primed mice survived and CD70 blockade improved the time to
recovery of the mice by 2–3 days (Fig 4F). In contrast to CD70 blockade as well as treatment
with IL-2 neutralizing antibodies, administration of exogenous IL-2 to mice challenged with
IAV failed to improve recovery (Fig 4G). These findings suggest that the protective efficacy of
vaccine-primed memory CD4 T cells can be improved by reducing their IL-2 production.
IL-2 directly drives broad lung inflammation that synergizes with viral
infection
Our results imply that the improved protective efficacy of the Il2-/- memory CD4 T cells in the
adoptive transfer model employed here is due largely to differences in the inflammatory
response generated upon infection. IL-2 is known to activate innate and adaptive immune
cells such as NK cells and CD8 T cells but also drives T reg responses that have anti-inflamma-
tory actions [43]. Though administration of IL-2 has been reported to promote systemic
inflammation and febrile illness in cancer patients [44], detailed analysis of how IL-2 impacts
the lung environment is lacking. We thus analyzed whether providing IL-2 in the absence of
memory CD4 T cell transfer would directly enhance inflammatory cytokine and chemokine
expression in the lung, even in the absence of IAV infection.
We first administered soluble IL-2 or IL-2:anti-IL-2 antibody (clone S4B6) complexes (IL-
2C) [45–47] to unmanipulated mice by i.p. injection for 3 consecutive days and analyzed lung
homogenates and serum for changes in cytokine and chemokine expression. We previously
found that this regime, employing 2 μg of IL-2, restored memory CD4 T cell generation from
Il2-/- CD4 T cells to WT levels in an IAV model, indicating its ability to deliver physiologically
relevant IL-2 signals in vivo [19]. Strikingly, IL-2C treatment drove strong expression of a
number of analytes such as IL-6, IFN-γ, IL-17, and G-CSF (S3A Fig) detected in Fig 2, particu-
larly in the lung and to a lesser extent in the serum.
The inflammatory factors seen in the lung following systemic IL-2 administration could
originate from other sites. However, when compared to the response seen with i.p. administra-
tion, an even more robust response was seen in the lung when IL-2C was administered intra-
nasally (Fig 5A). This supports the conclusion that beyond the known ability of IL-2 to
stimulate vascular leak and pulmonary edema [46, 48], the lung environment is extremely sen-
sitive to rapid IL-2-dependent induction of inflammatory cytokines and chemokines, even in
IL-2 drives potent inflammatory responses in the lung
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the absence of infection. As the 2 μg dose of IL-2C may deliver sustained IL-2 signaling not
typically achieved during immune responses, we titrated the amount of IL-2 used. The pro-
inflammatory impact of the IL-2C was proportional to the dose administered, with significant
pro-inflammatory effects in analytes such as CCL2 arising with even 0.5 μg of IL-2 and broad
effects seen at 1 μg. The impact of the IL-2C was abrogated by pre-treating hosts with blocking
antibody against CD122 (S3B Fig), confirming that IL-2 itself rather than potential contami-
nants in reagents was responsible for the inflammatory impact.
In agreement with previous observations [45], IL-2 and IL-2C treatment also caused the
expansion of several major leukocyte populations in the spleen (S3C Fig). Some of these pat-
terns were also seen in the lung. In particular, IL-2C treatment dramatically expanded NK cells
and to a lesser extent CD8 and CD4 T cells as well as inflammatory CD45+ MHC-II+ CD11b
+ Ly6C+ APC [49] (S3C and S3D Fig). Given the dramatic effect of IL-2C administration on
the lung environment, we assessed pulmonary mechanics in uninfected animals receiving IL-
2C. When compared to untreated controls, the IL-2C-driven inflammatory response corre-
lated with decreased respiratory function (Fig 5B).
Fig 5. IL-2 drives potent inflammatory responses in the lung that impair respiratory mechanics. IL-2Cs containing
2 μg of IL-2 were administered to naive BALB/c mice either i.p. or i.n. for 3 days. On d4, (a) inflammatory responses in
lung homogenates were measured (3 mice per group; 1 of 2 experiments). In separate experiments, (b) respiratory
rates, minute volumes, and enhanced pause (PenH) were measured on the indicated days (5 mice per group per day; 1
of 2 experiments). All error bars represent the standard deviation, and � P< 0.05, ��� P< 0.001, ���� P< 0.0001.
https://doi.org/10.1371/journal.ppat.1007989.g005
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We next tested whether and how IL-2 impacts the outcome of primary IAV infection
by treating unprimed WT mice with IL-2C for the first 3 days of a 0.2 LD50 A/PR8 chal-
lenge. Infected mice also treated with IL-2C displayed higher levels of a broad array of
cytokines and chemokines in the lung compared to mice only infected with IAV or mice
only treated with IL-2C (Fig 6A), indicating strong synergy between infection-induced
and IL-2-dependent inflammatory pathways. However, histopathological changes were
not appreciably enhanced in mice receiving IAV and IL-2C versus mice treated with only
IAV or only with IL-2C (Fig 6B and S4 Fig), agreeing with the lack of histological changes
in recipients of WT or Il2-/- memory CD4 T cells following IAV infection (Fig 3). Never-
theless, IL-2C treatment for 4 instead of 3 days resulted in acute death of infected mice,
even when lower amounts of IL-2 were used (Fig 6C). In marked contrast, when IL-2C
treatment was initiated at later time-points (5 to 9 dpi) that coincide with the onset of
viral clearance, all mice survived (Fig 6D). Thus, IL-2 signals delivered early but not at
later timepoints of infection when T cell effectors reach their peak, potently enhance acute
IAV-induced recruitment and/or activation of inflammatory cells in the lung and trans-
form a mild illness to a fatal infection.
Fig 6. Early IL-2 synergizes with IAV to drive lethal inflammatory responses. Uninfected and sublethal 0.2 LD50 A/
PR8-OVAII infected BALB/c mice were treated with PBS or IL-2Cs containing 2 μg of IL-2 for 3 days. On day 4,
inflammatory responses in lung homogenates were measured. The levels of cytokines and chemokines detected are
shown in (a) (3 mice per group; 1 of 3 experiments). The dashed line in bar graphs represents the level of analyte
detected with IL-2C treatment alone. In separate experiments, lungs were evaluated blindly and scored for
inflammation in the bronchi, blood vessels, and alveoli (b). IL-2C treatment with the indicated amount of IL-2 was
extended to 4 days (c) or given on the indicated days (d) and mortality monitored (3–5 mice per group; 1 of 3
experiments). All error bars represent the standard deviation, and � P< 0.05, ��� P< 0.001, ���� P< 0.0001.
https://doi.org/10.1371/journal.ppat.1007989.g006
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IL-2 induced NK cells are major contributors of lung inflammation and
fatal outcomes
Since NK cells and neutrophils were enhanced by IL-2C, and are prominently involved in driv-
ing IL-2-dependent vascular leak [50, 51], we determined their involvement in the IL-
2-induced inflammatory response. We first characterized the dynamics of NK and neutrophil
responses in the lung at 3 dpi in naïve recipients of WT or Il2-/- memory CD4 T cells, or in
controls not receiving cell transfer. While total numbers of NK cells in both WT or Il2-/- mem-
ory CD4 T cell recipients were similar, significantly more activated (CD44hi and IFN-γ+) NK
cells were detected in WT memory CD4 T cell recipients (Fig 7A). No differences in total neu-
trophil number or activation (SSChi CD69hi) were seen (Fig 7B). Significantly more activated
NK cells were also detected at 4 dpi in isotype antibody-treated recipients of WT memory CD4
T cells than in recipients treated with CD70 blocking antibody (Fig 7C), in which reduced lev-
els of paracrine IL-2 are detected (Fig 4B).
We next evaluated the ability of lung-resident memory CD4 T cells isolated from IAV-
primed mice to modulate NK cell responses in the presence and absence of IL-2 neutralizing
antibody to ensure that the observations made with in vitro-primed memory populations accu-
rately recapitulate elements of the IAV-primed responses. Polyclonal IAV-primed lung-resi-
dent memory CD4 T cells were transferred intranasally to naïve recipients as previously
described [12] and lung NK cell responses following IAV infection analyzed on 4 dpi. Both the
number of total NK cells as well and activated NK cells were reduced when IL-2 was neutral-
ized in lung-resident memory CD4 T cell recipients (Fig 7D), mirroring findings obtained
with in vitro-primed memory CD4 T cells.
Finally, we tested whether memory CD4 T cell-derived IL-2 could impact NK cell responses
in lungs imprinted by prior IAV infection [52] rather than in the models above assessing mem-
ory CD4 T cell responses in otherwise naive mice. We transferred WT memory CD4 T cells to
naive hosts and primed with IAV. At 60 dpi, cognate peptide was administered intranasally to
recall the donor CD4 T cells in the lung [31]. We analyzed lung NK cells 4 days after peptide
administration in mice treated with isotype or IL-2 neutralizing antibodies and found a reduc-
tion in activated, but not total NK cells in the absence of IL-2 signaling (S5 Fig). Thus, using
multiple approaches, we find that IL-2 production from memory CD4 T cells following TcR
stimulation significantly impacts the acute activation profile of NK cells in the lung.
Given the results above and observations that NK cells can maximize neutrophil responses
in vivo [53], we next depleted NK cells in naïve mice receiving WT memory CD4 T cell prior
to IAV challenge to determine whether and how NK cells impact the outcome of infection. NK
cell depletion resulted in reduced weight loss and earlier recovery (Fig 8A and 8B), phenoco-
pying the improved outcomes seen in Il2-/- versus WT memory CD4 T recipients depicted in
Fig 3, as well that of animals treated with CD70 blocking antibody in Fig 4. Even though they
are known to contribute to IL-2 driven vascular leak, additional depletion of neutrophils did
not appreciably alter the course of IAV infection (Fig 8A and 8C).
The involvement of NK cells in hampering CD4 T cell memory mediated protection
prompted us to determine the extent to which IL-2-induced NK cell responses directly con-
tribute to the production of acute inflammatory factors. To directly test this, we depleted NK
cells prior to treating naïve mice with IL-2C and measured inflammatory cytokines and che-
mokines in the lungs. NK cell depletion decreased levels of all cytokines and chemokines
enhanced by IL-2C treatment during IAV infection (Fig 8D), demonstrating the IL-2-depen-
dent ability of NK cells to markedly shape acute pulmonary inflammation. Finally, to firmly
establish a detrimental role for IL-2-driven NK cell responses in the lung during IAV infection,
we depleted NK cells in naïve mice prior to IL-2C administration and sublethal IAV challenge.
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Remarkably, NK cell depletion protected IAV-challenged WT and Rag2-/- mice from acute IL-
2C-dependent death (Fig 8E).
In summary, our results using both reductionist models and analysis of intact mice
responding to IAV strongly suggest that IL-2 produced by memory CD4 T cells can drive
enhanced inflammatory responses in the lung. A major mechanism involved in driving this
response is the IL-2-dependent promotion of early NK cell activity that can detrimentally
impact the resolution of IAV challenge.
Discussion
Defining the most incisive correlates of protective memory T cells in a disease-specific manner
is critical to improve monitoring of clinical responses and to promote tailored attributes of T
cells induced by vaccination. Fully understanding the impact of tissue environments on the
outcome of memory T cell recall is equally important but is poorly understood. Here, we show
that during memory CD4 T cell-mediated protective immune responses against IAV, their IL-
2 production induces enhanced proinflammatory cytokine production and NK cell responses
leading to delayed recovery and compromised lung function. Welsh and collaborators have
noted the rheostat nature of NK cell function after viral infection and the pathogenic impact of
too many NK cells during medium and high dose LCMV infection [54]. In the setting of IAV,
the beneficial versus detrimental impact of NK cells and neutrophil responses remains contro-
versial [55, 56]. Our results suggest that the relative amount of IL-2 available during the early
Fig 7. Memory CD4 T cell derived IL-2 induces NK cell activation. Unprimed BALB/c hosts received WT or Il2-/-
memory DO11.10 CD4 T cells and were infected with 2 LD50 dose of A/PR8-OVAII virus. On day 4, (a) total numbers
(left), activated (center), and IFN-γ cytokine producing NK cells (right) and (b) total and activated neutrophils in the
lung were assessed by flow cytometry (3–5 mice per group; 1 of 3 experiments). In (c), the number of activated NK
cells in the lung of WT memory CD4 T cell recipients in the presence and absence of CD70 blocking antibody (Ab)
was determined 4 dpi (4 mice per group; 1 of 2 experiments). In separate experiments, lung resident memory CD4 T
cells were isolated on 21 dpi from IAV-primed mice and 1 x 106 administered through the intranasal route. Recipient
mice were infected with 2 LD50 of A/PR8 and on day 4, (d) total numbers (left) and activated (right) NK cells in the
lung were assessed (4 mice per group; 1 of 2 experiments). All error bars represent the standard deviation, and �
P< 0.05, �� P< 0.01, ��� P< 0.001.
https://doi.org/10.1371/journal.ppat.1007989.g007
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phases of the immune response can be an important contextual determinant in regulating the
positive versus negative impact of these innate subsets.
Our findings suggest that, at least in the case of IAV infection, the ability of memory CD4 T
cells to produce high levels of IL-2 in conjunction with IFN-γ cannot alone be taken as an indi-
cator of superior protective potential. They do not, however, necessarily contradict the general
concept that multi-cytokine-producing Th1 memory cells are more protective than cells only
able to secrete IFN-γ [57]. Indeed, polyfunctional memory CD4 T cells express a unique
molecular signature compared to single IFN-γ producers [58]. Moreover, there are very few
differences in the transcriptome of wild-type and IL-2-deficient memory CD4 T cells respond-
ing against IAV [15]. These observations support the concept that key protective molecular
signatures of multi-functional CD4 memory may be independent of IL-2 expression during
Fig 8. NK cells are major contributors to IL-2-induced morbidity and mortality. OT-II CD4 memory T cell driven
morbidity (a) following 2 LD50 A/PR8-OVAII infection was assessed in C57BL/6 mice in the absence and presence of
NK cell (PK136) depleting antibody only or in addition to neutrophil (1A8) depleting antibody (3 mice per group; 1 of
3 experiments). Representative staining confirming the depletion of NK cells (b) and neutrophils (c) is shown. In (d),
IL-2Cs containing 2 μg of IL-2 were administered to naive C57BL/6 mice for 3 days in the presence of isotype or NK
cell (PK136) depleting antibody. Inflammatory responses in lung homogenates were measured on day 4 (n = 3 mice
per group in replicate experiments). In (e), A/PR8-OVAII infected (2500 EID50) WT C57BL/6 and Rag2-/- mice were
treated with PBS or IL-2Cs containing 2 μg of IL-2 for 3 days together with isotype or NK depleting antibody and
survival monitored (3 mice per group; 1 of 3 experiments). All error bars represent the standard deviation, and �
P< 0.05, �� P< 0.01, ��� P< 0.001, ���� P< 0.0001.
https://doi.org/10.1371/journal.ppat.1007989.g008
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antigenic recall, and as we have shown, IL-2 may instead have its positive activity primarily at
the effector stage to promote CD4 T cell memory generation [19].
Although we observed similar impacts using TcR transgenic and polyclonal CD4 T cells, a
comprehensive understanding of how and when IL-2 produced by CD4 T cell populations
impacts infection requires further study. For example, CD4 T cells with different TcR specifici-
ties have been shown to produce different amounts of IL-2 upon restimulation with cognate
IAV peptides [59], and both higher doses of antigen and higher avidity T cell responses lead to
greater IL-2 production [60]. These findings indicate that responses against certain antigens
may be more or less impacted by the mechanisms described here. Furthermore, optimal CD4
T cell-mediated IAV clearance requires synergy between many different specialized subsets
[61–63]. Whether IL-2 from subsets other than Th1-like cells similarly impacts recall against
IAV requires exploration, but we stress that the majority of CD4 T cells responding to IAV fit
general Th1-like criteria.
Additional studies are also required to determine if IL-2 production from memory CD4 T
cells similarly impacts responses against other pathogens, as well as in other tissues. Adjuvant
effects following IL-2 administration observed during systemic viral infection support that
memory CD4 T cell-derived IL-2 may have similar proinflammatory effects in this setting
[64]. However, that we found a stronger impact of IL-2 on inflammation in the lung than in
the serum, even when IL-2 was administered systemically, suggests the lung and responses
against respiratory infections may be particularly sensitive to IL-2. Indeed earlier studies
found exogenous IL-2 administration to cause cellular proliferation only in specific tissues,
including the lung [65]. We speculate that IL-2 production from vaccine-induced memory
CD4 T cells may in some cases be a component of their immunopathological impact, such as
that observed during chronic LCMV infection [22].
We previously found that blocking CD70 during IAV priming dramatically decreased the
number of memory CD4 T cells formed [19]. The impact on memory generation was due to a
reduction of CD27-dependent autocrine IL-2 production induced by cognate interactions
with CD70+ dendritic cells. Here, we found CD70 blockade to reduce inflammation driven by
memory CD4 T cells responding to IAV. Interestingly, CD70 blockade significantly decreased
IL-2 production as well as IFN-γ production by memory CD4 T cells. While higher levels of
IFN-γ have been implicated in increasing susceptibility to primary IAV infection [66], we have
shown that IFN-γ signaling does not significantly impact the ability of memory CD4 T cells to
drive protective inflammatory responses against IAV [26, 31]. Thus, while we cannot formally
rule out that changes in IFN-γ and other factors have no impact on the improved responses
seen with blocking CD70, our data strongly supports the hypothesis that changes in IL-2 pro-
duction play a central role in this process. Collectively, our observations suggest that the
CD27-CD70 pathway may be targeted as a temporal rheostat to modulate CD4 T cell immu-
nity: during priming, targeting the CD70-CD27 pathway to enhance IL-2 production can
serve to boost the efficiency of memory generation, while early during recall, blocking this
pathway may help to restrain IL-2-driven inflammation originating from memory CD4 T
cells.
Given the potent and broad-ranging proinflammatory activity of IL-2, we predict that
mechanisms must be in place to limit its impact. The lung may be particularly sensitive to IL-
2-driven inflammation because of endothelial cell expression of functional IL-2 receptors [46].
We found previously that while CD4 T cell effectors responding to IAV in the spleen and
draining lymph nodes produce high levels of IL-2, only about 10% of cells responding in the
lung at the peak of the anti-viral response demonstrate robust IL-2 production [10]. This is in
stark contrast to the strong IL-2 production potential observed from CD4 T cells that develops
in the lungs only after the clearance of virus as well as at memory timepoints [12, 67, 68]. We
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propose that these findings reflect two distinct kinds of control on IL-2 production by CD4
T cells. First, control of T cell cytokine production appears to be an inherent property of
the lung environment [69], which may serve to buffer against IL-2-induced inflammation
to maintain maximal pulmonary function. Second, further controls on IL-2 production are
likely induced by infection. For example, PDL-1, which dramatically impedes IL-2 produc-
tion by activated T cells upon ligation of PD-1 [70, 71], is strongly upregulated in the lung
early in the course of IAV infection [72, 73]. The extent to which the capacity of lung IAV-
specific CD4 T cells to produce high levels of IL-2 during the transition to memory follow-
ing viral clearance [67] is resultant from downmodulation of inhibitory molecules such
as PDL-1 versus CD4 T cell-intrinsic mechanisms warrants further study. Interestingly,
IL-2 production by CD4 T cells is needed to promote production of the anti-inflammatory
cytokine IL-10 by CD8 T cells responding to IAV [74], which make little of their own IL-2
during heterosubtypic responses [8]. IL-10+ CD8 T cells protect mice against lethal IAV-
induced inflammation in some [75] but not other [32] models. Induction of IL-10+ CD8 T
cells by CD4 T cell-derived IL-2 may thus act as further layer of buffering against damaging
inflammation during respiratory infections. The impact of these restraining mechanisms
likely lessens following pathogen clearance.
Therapeutic delivery of IL-2, such as by systemic IL-2C treatment using the S4B6 clone and
1–2 μg of recombinant IL-2 has seen increasing use in experimental models to modulate CD8
T cell and NK cell populations in vivo to improve responses against pathogens and cancers
[43]. Our results stress the importance of careful evaluation of how these treatment regimens
impact inflammatory environments when interpreting experimental outcomes. Furthermore,
we stress that while IL-2 production can be boosted or restored by the systemic blockade of
checkpoint inhibitors [76, 77], how production of IL-2 by T cells responding to respiratory
infection impacts patient outcome in such settings, including cancer therapy, remains to be
determined. Our results argue the clinical use of IL-2 and engineered IL-2 and IL-15 [78]
should be viewed with caution, given the fatal outcomes observed when IL-2C treatment
synergized with mild, low-dose, IAV infection.
Methods
Ethics statement
Experimental animal procedures were conducted in accordance with guidelines outlined by
the Office of Laboratory Animal Welfare (OLAW), National Institute of Health, USA. Proto-
cols were approved by the Animal Care and Use Committee at Trudeau Institute (Saranac
Lake, NY) protocol 00–33, the Institutional Animal Care and Use Committee of the University
of Massachusetts Medical School (Worcester, MA) protocol A-2198, and the University of
Central Florida (Orlando, FL) protocol 18–30.
Mice
Naïve CD4+ T cells were obtained from 5 to 8-week-old male or female DO11.10 Thy1.2/
Thy1.1 and Il2-/- DO11.10 Thy1.2/Thy1.1 mice originally provided by A. Abbas (UCSF).
Recipients of cell transfers were male BALB/c.Thy1.2 or BALB/c.Thy1.1, nude, JHD, or SCID
mice that were at least 8 weeks old. In some experiments, naïve CD4 T cells were obtained
from 5 to 8-week-old male OT-II Thy1.2/1.1 mice and C57BL/6 and Rag2-/- male recipients
were used. Nude, Rag2-/-, JHD, and SCID mice were purchased Charles River, Taconic, or Jack-
son Laboratories. All other mice were obtained from Jackson Laboratories or the breeding
facility at Trudeau Institute, the University of Massachusetts Medical School, or the University
of Central Florida.
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CD4 T cell isolation and in vitro-primed memory generation
Naïve CD4+ T cells were obtained from pooled spleen and peripheral lymph nodes as previ-
ously described [24]. Briefly, cells were purified by nylon wool and percoll density gradient
separation. CD4 T cells were isolated by positive CD4 MACS selection (Miltenyi). Resulting
CD4+ cells routinely expressed a characteristic naive phenotype (small size, CD62Lhi, CD44lo
and CD25lo)>97% TcR+. TH1-polarized effectors were generated in vitro as described [5].
Briefly, naïve WT or Il2-/- CD4 T cells were cultured with an equal number of irradiated APC
(2x105 per mL) in the presence of exogenous IL-2 (20 ng per mL), 2 ng per mL IL-12 (Pepro-
tech), 10 μg per mL anti-IL-4 antibody (11B11; Bioxcell), and 5 μM OVAII peptide. In vitro-
primed memory cells were obtained by thoroughly washing effector cultures at 4 days and re-
culturing the cells in fresh media for at least 3 days in the absence of Ag and exogenous cyto-
kines. Live cells were isolated by Lympholyte separation (Cedarlane). All donor CD4 T cells
were adoptively transferred in 200 μl phosphate buffered saline (PBS) by intravenous (i.v.)
injection. A number of donor cells previously determined to protect against lethal IAV infec-
tion, 5 x 106, was transferred. In some experiments, donor CD4 T cells were labeled with
CFSE, as previously described [10], prior to adoptive transfer to monitor in vivo proliferation.
In some experiments, lung resident memory CD4 T cells were isolated from IAV-primed mice
and 1 x 106 adoptively transferred to recipient mice through the intranasal route as previously
described [12].
Virus stocks and infections
Influenza A/Puerto Rico/8/1934 (PR8) (H1N1) originating from stocks prepared at the Tru-
deau Institute and in use in experiments since 1997, A/PR8-OVAII (H1N1) from stock
obtained from P. Doherty at St Jude’s Children’s Hospital [79], and the cold-adapted attenu-
ated strain A/Alaska/6/1977 CR-29, (H3N2) virus kindly provided by S. Epstein, NIH were
produced in the allantoic cavity of embryonated hen eggs at the Trudeau Institute and the
lethal dose (LD50), egg infective dose (EID50) or tissue culture infective dose (TCID50) charac-
terized. Mice were infected intranasally under light isoflurane anesthesia (Webster Veterinary
Supply) with the indicated doses of virus in 50 μl PBS and morbidity and mortality monitored.
Donor cell injection and viral infection occurred on the same day. In some experiments, 5 μg
of cognate peptide was administered intranasally to mice that had received donor memory
CD4 T cells and IAV primed 60 days prior. The recovery day, or the day when animals began
to regain weight following infection, was also determined.
Detection of IAV titer
Pulmonary viral titer was determined by quantitation of viral RNA. RNA was prepared from
whole lung homogenates using TRIzol (Sigma-Aldrich), and 2.5 μg of RNA was reverse tran-
scribed into cDNA using random hexamer primers and Superscript II Reverse Transcriptase
(Invitrogen). Quantitative PCR was performed to amplify the acidic polymerase (PA) gene of
A/PR8-OVAII using an ABI Prism 7700 Sequence Detector (Applied Biosystems) with 50 ng
of cDNA per reaction and the following primers and probe: forward primer, 5’-CGGTCCA
AATTCCTGCTGA-3’; reverse primer, 5’CATTGGGTTCCTTCCATCCA-3’; probe, 5’-6-
FAM-CCAAGTCATGAAGGAGAGGGAATACCGCT-3’. Data were analyzed with Sequence
Detector v1.7a (Applied Biosystems). The copy number of the PA gene per 50 ng of cDNA was
calculated using a PA-containing plasmid of known concentration as a standard. The number
of copies of PA gene per lung is presented.
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Cytokine complex, receptor blockade, and depleting antibody treatments
Mice were treated for the indicated days with injections of cytokine or cytokine: anti-cytokine
monoclonal antibody complexes. For IL-2 complexes (IL-2C), mice received 2 μg per day of
recombinant IL-2 (eBioscience) premixed with 20 μg of anti-mouse IL-2 monoclonal antibody
clone S4B6-1 (S4B6) (BD Pharmingen). In certain experiments, the amount of IL-2 in the
complexes was varied, as indicated. Complexes were incubated at room temperature for 20
minutes (min.) before intraperitoneal (i.p.) injection in 200 μL of PBS. IL-2C in 50 μL of PBS
were also administered intranasally (i.n.). When IL-2 was administered as free cytokine, ani-
mals were treated with 20 μg per day in 200 μL of PBS injected i.p.
For some experiments, mice were treated as indicated with 0.25 mg per day of anti-CD122
(IL-2 Rβ) antibody (5H4) to block IL-2 signaling, 0.25 mg per day anti-IL-2 antibodies (S4B6
and JES6-1A12) to neutralize IL-2, 0.5 mg per day of anti-CD70 antibody (FR-70) to block
CD70 signaling, 0.25 mg per day of anti-NK1.1 (PK136) to deplete NK cells, 0.5 mg of anti Ly-
6G Ab to deplete neutrophils (1A8), or with appropriate isotype control antibody (all Bioxcell).
Antibody was delivered by i.p. injection in 200 μL of PBS.
Tissue preparation and flow cytometry
At different time points after virus infection, blood and lungs were obtained from euthanized
animals for Luminex multiplex analysis. Lungs were harvested and homogenized in RPMI
1640 media supplemented with 2mM L-glutamine, 100 IU penicillin, 100 μg/mL streptomycin
(Invitrogen), 10 mM HEPES (Research Organics), 50 μM 2-mercaptoethanol (Sigma-Aldrich)
and 7.5% fetal bovine serum (Hyclone) and serum collected from blood.
Alternatively, for flow cytometry, mice were euthanized by cervical dislocation followed by
exsanguinated by perforation of the abdominal aorta. Lungs were perfused by injecting 10 ml
of PBS in the left ventricle of the heart. Lungs and spleen were prepared into single cell suspen-
sions by mechanical disruption of organs and passage through a nylon membrane. Flow
cytometry was performed as previously described [24] using fluorochrome-labeled antibodies
at manufacturer’s recommended dilutions for surface staining including anti-Thy1.1 (OX-7),
anti-Thy1.2 (53–2.1), anti-CD4 (RM4.5 and GK1.5), anti-CD8 (53–6.7), anti-CD45.2 (104),
anti-γδ TcR (GL3), anti-β TCR (H57-597), anti-CD3 (17A2), anti-CD49d (R1-2), anti-CD25
(PC61), anti-CD44 (1M7.8.1), anti-CD69 (H1.2F3), anti-CD11b (M1/70), anti-Gr-1 (RB6-
8C5), anti-MHC-II (M5/114.15.2), and anti-Ly6C (HK1.4). In some experiments, tissue resi-
dent memory CD4 T cells were identified by intravenous administration of 3 μg of fluoro-
chrome-labeled antibody 3 minutes prior to euthanasia and tissue harvest [12].
Intracellular cytokine staining was performed as previously described [19]. Briefly, cells
were treated with PMA and Ionomycin for 4 hours or stimulated overnight with cognate pep-
tide presented by APC, with Brefeldin A added after 2 h. Cells were then surface stained, fixed
for 20 min. in 4% paraformaldehyde, and permeabilized by 10 min. incubation in 0.1% sapo-
nin before staining for cytokine by the addition of anti-IFN-γ and anti-IL-2 fluorescently
labeled antibodies. Analysis was performed using FACS Canto II and LSRII instruments (BD
Biosciences) and FlowJo (Tree Star) analysis software.
Detection of inflammatory cytokines and chemokines and BAL albumin
Levels of cytokines and chemokines in lung homogenates or serum were determined using
mouse multiplex kits (Invitrogen and Millipore) read on a Bio-Plex Multiplex 200 Luminex
reader (Bio-Rad). Levels of serum albumin in the BAL fluid were determined using a Mouse
Albumin ELISA Quantification Kit as per manufacturer’s instructions (Bethyl Laboratories
Inc.).
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Histology
For assessment of immunopathology following viral infection and IL-2C treatment, lungs
lobes were isolated and immediately fixed in 10% neutral buffered formalin. Lung samples
were subsequently processed, embedded in paraffin, sectioned, placed on L-lysine-coated
slides, and stained with Hematoxylin and Eosin (H&E) using standard histological techniques.
Sections were graded blindly from 0 to 4, for the extent of inflammatory cell infiltration and
damage of bronchi, arteries or alveoli by a certified pathologist (S. Sell).
Measurement of pulmonary mechanics
Non-invasive whole-body plethysmography (WBP) (Buxco) was employed to measure respira-
tory rates (breaths/min.), minute volumes (mL/min.), and enhanced pause PenH, on con-
scious, unrestrained animals following IAV infection and IL-2C treatment. The minute
volume is defined as the volume of air exchanged during a 1-min. interval and is calculated as
follows [respiratory rate X tidal volume].
Statistical analysis
Group sizes of n = 3 to 15 were employed. Unpaired, two-tailed, Students t-tests,1 = 0.05,
were used to assess whether the means of two normally distributed groups differed signifi-
cantly. One-way ANOVA analysis with Bonferroni’s multiple comparison post-test was
employed to compare multiple means. Two-way ANOVA analysis with repeated measures was
also employed in some experiments. The Log Rank test was used to test for significant differ-
ences in Kaplan-Meier survival curves. All error bars represent the standard deviation. Signifi-
cance is indicated as � P< 0.05, �� P< 0.005, ��� P< 0.001, ���� P< 0.0001.
Supporting information
S1 Fig. Engraftment and response of WT and Il2-/- memory CD4 cells in congenic adoptive
transfer recipients. Unprimed BALB/c recipients of WT or Il2-/- memory DO11.10 CD4 T
cells were challenged with a 2 LD50 dose of A/PR8-OVAII virus. On indicated days, engraft-
ment and expansion of donor cells was assessed in spleens, draining lymph nodes (dLN), and
lungs of recipient mice. Representative donor cell expression of the congenic marker and CD4
on gated lymphocytes is shown in (a) and donor cell expansion via loss of CFSE shown in (b).
Percentages represent the frequency of donors among total lymphocytes (3–5 mice per group;
1 of 3 experiments).
(EPS)
S2 Fig. IL-2 production is not needed for IAV-specific memory CD4 T cell-mediated pro-
tection in T and B cell deficient hosts. The indicated unprimed immunodeficient recipient
hosts received WT or Il2-/- memory DO11.10 CD4 T cells and were challenged with a 2500
EID50 dose of A/PR8-OVAII virus. Morbidity was monitored (3–5 mice per group; 1 of 3
experiments). All error bars represent the standard deviation and � P< 0.05.
(EPS)
S3 Fig. IL-2 drives potent inflammatory responses in the lung. Naive BALB/c mice were
treated with PBS, 20 μg of IL-2, or IL-2Cs containing 2 μg of IL-2 for 3 days. On day 4, inflam-
matory responses in lung homogenates and serum were measured (a) (summary from 3 exper-
iments containing 3 mice per group). In separate experiments, mice were treated with IL-2C
containing the indicated amount of IL-2 without or with anti-CD122 antibody to block the IL-
2R. Inflammatory responses in lung homogenates were measured on d4 (b) (3 mice per group;
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1 of 2 experiments). Lymphocyte populations in the spleen and lung of IL-2 or IL-2C treated
animals were enumerated and compared to control mice (c). The frequency of inflammatory
CD45+ MHC-II+ CD11b+ Ly6C+APC were also determined in the lung of mice treated with
IL-2C or PBS alone (d). All error bars represent the standard deviation, and � P< 0.05, ��
P< 0.01, ��� P< 0.001, ���� P< 0.0001.
(EPS)
S4 Fig. IL-2 contributes to alveolar and perivascular histopathology. Uninfected and low-
dose, sublethal 0.2 LD50 A/PR8-OVAII infected BALB/c mice were treated with PBS or IL-2Cs
containing 2 μg of IL-2 for 3 days. Representative photomicrographs of H & E stained tissue
sections of lungs on 4 dpi are shown, Br: bronchus; Ar: artery.
(EPS)
S5 Fig. Memory CD4 T cell derived IL-2 induces NK cell activation in IAV primed environ-
ments. Unprimed BALB/c hosts received WT memory CD4 T cells and were infected with 0.5
LD50 A/PR8-OVAII virus. On day 60 and 62 post priming, 5 μg of cognate peptide was admin-
istered and total numbers and activated NK cells assessed by flow cytometry (4 mice per
group) and � P< 0.05.
(EPS)
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